. Mattsson W, Borgstrom S, Landberg T. A weekly schedule of low dose doxorubicin in treatment of advanced breast cancer. Clin Ther 1982,5,193-203 . to have a SWOG performance status of 3 or less; white cells 3.500/$ or more and platelets 100,000/~1 or more; serum creatinine 177 PrnoVl or less and serum bilirubin 34 pmol/l or less; and patients' informed consent. MGBG was administered weekly at 600 mg/m* as an intravenous infusion in 150 ml DSW or normal saline over 30 min or more. Dose escalations of 100 mg/m* were given if no toxicity was noted. Weekly doses were reduced by 100 mg/m* for severe (SWOG grade 3) toxicities. One course of therapy was delined as 4 weeks of MGBG. SWOG criteria were used to assess tumour response.
45 of the 46 patients entered were eligible (Table 1) . 1 patient had no measurable disease. 20 of the eligible patients (44%) had at least one or more courses. There were no complete or partial responses. The exact 95% confidence interval of 0 out of 45 is O-8%.
Toxicities in the study consisted of grade 3 (severe) or greater nausea and vomiting in 16% ofpatients, with 2 patients requiring admission. Grade 3 diarrhoea occurred in 9% of patients (1 admitted). 1 patient had grade 4 mucositis and 1 had a perforated diverticulum leading to death. Other grade 2 or greater toxicities included fatigue and weakness in 3 patients, hypoglycaemia in 2, hypotension (under 90 mmHg systolic) in 2, weight loss in 4 patients (1 lost 4.5 kg and 1 lost 7.7 kg), and anaemia in 8. Toxicities were so troublesome that 8 patients refused additional treatments (usually after only l-3 doses).
Despite the protocol calling for failure on only one previous chemotherapeutic regimen it is clear the patient population was
